300. Armed to the teeth – human bite associated septic arthritis
Session: Poster Abstract Session: Bone and Joint Infections
Thursday, October 4, 2018
Room: S Poster Hall
Posters
  • ID Week poster Armed_poster.pdf (578.8 kB)
  • Background:

    Fight bite-related septic arthritis (FBSA) occurs when a joint is infected following a human bite injury. We aimed to describe the clinical features, treatment and outcomes of FBSA and compare these with native joint septic arthritis of other causes.

    Methods:

    Cases were obtained from a previously-described retrospective cohort of adult native joint septic arthritis admitted to Middlemore Hospital, Auckland, New Zealand from 1 January 2009 and 31 Dec 2014. FBSA cases were compared to small-joint non-fight bite septic arthritis (SJNFBSA), and all NFBSA. p-values of ≤0.05 were considered significant.

    Results:

    Sixty-seven FBSA and 476 NFBSA cases (including 183 SJNFBSA) were identified. Compared to SJNFBSA and all NFBSA, FBSA was associated with younger age (median 26 years vs. 49 and 52 respectively) and tobacco use, but lower rates of diabetes, osteoarthritis and renal failure. Osteomyelitis was more common and metastatic infection less common in FBSA (all p≤0.05).

    FBSA was more likely to be polymicrobial (76% vs. 30% and 20%), and to be caused by oral flora, oral streptococci, HACEK organisms and anaerobes. SJNFBSA was less likely to be caused by S. aureus than FBSA.

    FBSA was more commonly managed operatively than SJNFBSA and all NFBSA (93% vs. 79% and 81%) and received shorter antibiotic courses (median 2 weeks vs 4 and 5 weeks), more commonly orally (84% oral vs. 6% and 32%). Hospital length of stay for FBSA was shorter (median 4.5 days vs 6 and 9 days). Compared to all NFBSA, treatment failure was less common (7% vs 19%, p=0.0242) and there was a trend toward lower mortality (0% vs 5%, p=0.0604).

    Conclusion:

    FBSA represents a distinct subset of septic arthritis with differing morbidity and better outcomes than NFBSA. FBSA may be able to be safely managed with shorter, oral antibiotic regimens if adequate operative management is undertaken. Further studies are required to validate these findings.

    Stephen McBride, BHB, MBChB1, Jessica Mowbray, MBChB2, William Caughey, MBChB2, Edbert Wong, MBChB1, Christopher Luey, MBChB3, Ahsan Siddiqui, MB BS1, Zanazir Alexander, MBChB2, Veronica Playle, MBChB3, Timothy Askelund, MBChB3, Christopher Hopkins, MD4, Norman Quek, MBChB3, Katie Ross, MBChB3 and David Holland, MBChB FRACP FRCPA PhD3, (1)Department of Medicine, Middlemore Hospital, Auckland, New Zealand, (2)Department of Surgery, Middlemore Hospital, Auckland, New Zealand, (3)Middlemore Hospital, Auckland, New Zealand, (4)Infectious Diseases, Middlemore Hospital, Auckland, New Zealand

    Disclosures:

    S. McBride, None

    J. Mowbray, None

    W. Caughey, None

    E. Wong, None

    C. Luey, None

    A. Siddiqui, None

    Z. Alexander, None

    V. Playle, None

    T. Askelund, None

    C. Hopkins, None

    N. Quek, None

    K. Ross, None

    D. Holland, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.